Genexine
Genexine is a KOSDAQ-listed South Korean clinical-stage biopharmaceutical company developing long-acting biologics and bioPROTAC therapeutics across oncology, CKD anemia, and growth hormone deficiency, commercializing through regional channel partners including KGbio, Handok, and I-Mab.
- Company typePublic
- Founded2015
- HeadquartersSeongnam, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Genexine does
Genexine, Inc. is a South Korea-based, KOSDAQ-listed (ticker 095700) clinical-stage biopharmaceutical company founded in 2015 and headquartered in Gangseo-gu, Seoul, that develops innovative biologics for serious unmet medical needs across oncology, chronic kidney disease, growth hormone deficiency, and metabolic disorders. The company is built on three proprietary technology platforms: hyFc fusion technology for long-acting biologics, a therapeutic DNA vaccine platform, and the bioPROTAC/EPDeg targeted protein degradation platform (acquired via the October 2024 merger with EPD Biotherapeutics). Its clinical pipeline includes GX-E4 (Efepoetin alfa, long-acting erythropoietin for CKD-induced anemia, approved in Indonesia October 2023 and in multinational Phase 3), GX-H9 (Eftansomatropin alfa, weekly long-acting growth hormone in Phase 3, BLA planned in China), GX-I7 (Efineptakin alfa, long-acting IL-7 for immuno-oncology in Phase 2), GX-188E (therapeutic DNA vaccine for HPV-positive cancers in Phase 2), and bioPROTAC candidates GX-BP1 (lung cancer) and GX-BP2 (atopic dermatitis).
Genexine monetizes primarily through licensing, co-development, and technology-transfer arrangements with regional and global partners rather than direct sales. Commercial distribution is executed through channel partnerships: KGbio (joint venture with PT Kalbe Farma) for ASEAN markets, Handok for Korea, and I-Mab/Jumpcan for Greater China. The company has secured sizable technology-transfer deals (notably with I-Mab valued at up to $560M for GX-I7 China rights, and with Jegene Bio for immunosuppressant candidates worth up to KRW 1.91 trillion including milestones), and pursues combination-therapy clinical trials with checkpoint-inhibitor and CAR-T franchises owned by Merck, BMS, Novartis, and Roche/Genentech.
The customer base is structured around patients and physicians in oncology, nephrology, and endocrinology, but Genexine's immediate commercial counterparties are large pharma and regional commercialization partners. End-customer pricing is not publicly disclosed, as the company is clinical-stage with only one approved product to date. Leadership was restructured in late 2024 into a co-CEO model (Sungjune Hong and Jaehyun Choi) following the EPD Biotherapeutics merger, consolidating R&D direction around the expanded bioPROTAC platform alongside the legacy long-acting biologics portfolio.
Genexine firmographics
Firmographics- Name
- Genexine
- Legal name
- Genexine, Inc.
- Website
- https://genexine.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Genexine is a KOSDAQ-listed South Korean clinical-stage biopharmaceutical company developing long-acting biologics and bioPROTAC therapeutics across oncology, CKD anemia, and growth hormone deficiency, commercializing through regional channel partners including KGbio, Handok, and I-Mab.
- Ownership category
- akta.pro rank
Genexine industry classification
Industry- Product category
- Clinical-stage biopharmaceuticals (oncology, nephrology, endocrinology, rare disease)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Therapeutic Enzymes & Enzyme Replacement Therapies (ERT) (HLAAAAAK)
- akta.pro secondary industries
- Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services (HLAAACAM), Enzyme Replacement & Metabolic Disorder Therapies (HLAIAIAB), Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI)
Keywords
Where Genexine is headquartered
LocationHeadquarters
- HQ city
- Seongnam
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
Genexine business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Genexine product offering
Product offeringCore offering
Genexine is a clinical-stage biopharmaceutical company that discovers, develops, and seeks to commercialize innovative biologics (long-acting fusion proteins, therapeutic DNA vaccines, and targeted protein degraders) for serious unmet medical needs in oncology, nephrology, endocrinology, and rare diseases. Its commercial-stage lead product Efepoetin alfa (GX-E4/Efesa), a long-acting erythropoietin for chronic kidney disease-induced anemia, received its first market approval from Indonesian BPOM in October 2023, with multiple Phase 3 programs (GX-E4, GX-H9) advancing through clinical development globally.
Product overview
Genexine is a clinical-stage Korean biopharmaceutical company developing innovative biologics for serious unmet medical needs. The company's portfolio consists of multiple therapeutic candidates across oncology, rare diseases, and metabolic disorders, supported by three proprietary technology platforms: hyFc (long-acting fusion), bioPROTAC (targeted protein degradation), and DNA Vaccine. Key products include GX-I7 (long-acting IL-7 for immuno-oncology), GX-E4 (long-acting EPO for CKD anemia), GX-H9 (long-acting growth hormone), GX-188E (DNA vaccine for cervical cancer), and GX-BP1/GX-BP2 (bioPROTAC candidates for lung cancer and atopic dermatitis). Several products are in Phase 3 registration trials with market approval achieved for GX-E4 in Indonesia.
Differentiator
Problem solved
Functional benefit
Brands
- hyFc: Proprietary long-acting fusion platform technology for developing long-acting biologics
- EPDeg
Products and services
- GX-E4 (Efepoetin alfa / Efesa) Long-acting erythropoietin (EPO) bio-better for chronic kidney disease-induced anemia, using hyFc fusion platform technology to enable once every two weeks or four weeks injection versus more frequent dosing of conventional EPO. First market approval received from Indonesian BPOM in October 2023.
- GX-H9 (Eftansomatropin alfa) Long-acting recombinant human growth hormone developed using the hyFc platform for pediatric growth hormone deficiency (GHD), enabling weekly injection dosing compared to daily injections of conventional growth hormone therapies. Phase 3 showed non-inferior annualized height velocity of 10.76 cm/year vs 10.28 cm/year for daily Norditropin.
- GX-I7 (Efineptakin alfa) Long-acting interleukin-7 (IL-7) immunotherapy drug that amplifies T-cell numbers and enhances immune response, being developed in combination with global immuno-oncology drugs for triple-negative breast cancer (TNBC) and other cancers. Being advanced in the US market through NeoImmuneTech subsidiary.
- GX-188E (Tirvalimogene teraplasmid) First-in-class therapeutic DNA vaccine for HPV-positive cancers including cervical cancer and head and neck squamous cell carcinoma (HNSCC), designed to induce HPV antigen-specific immune responses. In Phase 2 trials; triple combination with GX-I7 and pembrolizumab achieved 63.6% major pathological response rate in HPV-positive HNSCC.
- GX-BP1 First-in-class SOX2-targeting bioPROTAC drug candidate using the EPDeg platform with lung-targeted mRNA-LNP delivery, designed to selectively degrade the SOX2 transcription factor for lung cancer treatment. Demonstrated up to 96% tumor growth inhibition in preclinical models.
- GX-BP2 STAT3-targeting bioPROTAC candidate for atopic dermatitis treatment, leveraging the EPDeg platform to directly degrade disease-causing proteins.
- GX-P1 (EGT-101) PD-L1-hyFc fusion protein designed for immune modulation following injury, being developed for secondary inflammation particularly malignant cerebral edema following stroke. Subject to ownership transfer to Egret Therapeutics (EGT-101) under March 2026 MOU.
- GX-G6 Long-acting therapeutic candidate for Type 2 Diabetes and Obesity being developed using the hyFc platform technology, currently in Phase 2/3 clinical trials.
Quantifiable outcome
- GX-E4 achieved 69.6% response rate vs 63.2% for Mircera in CKD-induced anemia Phase 3
- +3 more outcomes
Companies that use Genexine
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles4 records
Genexine technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Genexine partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered minor and core.
- Egret TherapeuticsminorEgret Therapeutics signed MOU with Genexine to acquire full ownership of GX-P1 (EGT-101), a PD-L1-hyFc fusion protein for immune modulation following injury. Transaction would grant Egret sole ownership for development of therapies for secondary inflammation, particularly Malignant Cerebral Edema following stroke.
- EPD BiotherapeuticscoreGenexine completed merger with EPD Biotherapeutics in October 2024. The merger integrates EPD Bio's bioPROTAC platform technology and talent into Genexine. EPD Bio founder Dr. Jaehyun Choi joined Genexine as representative director in charge of R&D. Merger ratio was 1:6.1924079. This strategic move strengthens Genexine's drug pipeline with innovative targeted protein degradation technology.
- I-MabcoreChinese partnership for GX-H9 development in China. I-Mab has partnered with Jumpcan for product launch and commercialization of eftansomatropin alfa in China. Phase 3 trial met primary endpoint with BLA submission planned in China.
- RocheminorGX-E4 Phase 3 clinical trial used Roche's Mircera as active comparator. Genexine has also partnered with Roche subsidiary Genentech for combination therapy development.
- Merck & Co. (MSD)minorCombination therapy clinical trials of GX-188E and GX-I7 with Keytruda (pembrolizumab) for cervical cancer and head and neck cancer treatment.
- NovartisminorCombination clinical trial of GX-I7 with Novartis CAR-T therapy Kymriah (tisagenlecleucel) for relapsed/refractory large B-cell lymphoma patients.
- BMSminorCombination clinical trial of GX-I7 with BMS Opdivo (nivolumab) for metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.
- HandokcoreStrategic partnership for co-development of GX-H9 (growth hormone deficiency treatment). Handok is co-developing and will commercialize the product in Korea.
- NeoImmuneTechcoreUS-based subsidiary developing GX-I7 (efineptakin alfa) for immune-oncology applications. NeoImmuneTech is advancing clinical development of long-acting IL-7 technology in the US market.
- PT Kalbe Farma (KGbio)coreJoint venture clinical-stage biotechnology company between Genexine and PT Kalbe Farma focused on bringing biologics medical innovation to international markets. Received first market approval for Efepoetin alfa (GX-E4) from Indonesian BPOM. Conducting multinational Phase 3 clinical trials across 11 countries in Europe and Asia.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Genexine competitors and assessment
Company assessmentDirect peers
- Hanmi Pharmaceutical: Korean pharmaceutical company developing long-acting biologics through its proprietary LAPS (Long-Acting Protein/Peptide) platform, directly comparable to Genexine's hyFc fusion technology for extending dosing intervals of therapeutic proteins.
- Alteogen: Korean biotech developing long-acting biologics and biosimilars with proprietary platform technologies, comparable to Genexine as a Korean clinical-stage biologics company with platform-based product portfolio.
Broad incumbents
- Celltrion: Larger Korean biotech specializing in biosimilars and novel biologics manufacturing, comparable as a Korean-headquartered biologics developer with global commercialization partnerships.
- Samsung Bioepis: Korean biosimilars-focused subsidiary of Samsung with broader commercial scale, comparable to Genexine as a Korean biologics developer targeting similar therapeutic areas (immunology, oncology supportive care).
- Amgen: Global biotech with Aranesp (long-acting darbepoetin) directly competing with Genexine's GX-E4 in the long-acting EPO category; comparable as a major established player in long-acting biologics.
- Roche: Makers of Mircera (methoxy polyethylene glycol-epoetin beta), the active comparator used in Genexine's GX-E4 Phase 3 trial; directly comparable as the established competitor in long-acting CKD anemia therapeutics.
- Novo Nordisk: Global leader in growth hormone therapy (Norditropin, Sogroya), directly comparable as the incumbent competitor to Genexine's GX-H9 long-acting growth hormone in pediatric GHD.
Emerging players
- Arvinas: Pioneer of small-molecule PROTAC technology where Genexine's new R&D co-CEO Dr. Jaehyun Choi previously worked; comparable as a targeted protein degradation platform company, though Genexine's bioPROTAC approach is differentiated by mRNA-LNP delivery.
- NeoImmuneTech: US-based subsidiary of Genexine developing GX-I7 (efineptakin alfa) long-acting IL-7 in immuno-oncology; closely related entity extending Genexine's pipeline into US clinical development.
- I-Mab Biopharma: Chinese biotech holding China rights to Genexine's GX-H9 and GX-I7 and formerly 8.1% owned by Genexine; comparable as an immuno-oncology partner with overlapping biologics programs.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Genexine social profiles
Digital presenceGenexine financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genexine leadership team
Management profileNumber of profiles
Profiles2 records
Genexine subsidiaries and ownership
Company hierarchySubsidiaries4 records
Genexine funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genexine M&A and investment
M&A and investmentM&A1 record
Investments7 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genexine
What does Genexine do?
Genexine is a clinical-stage biopharmaceutical company that discovers, develops, and seeks to commercialize innovative biologics (long-acting fusion proteins, therapeutic DNA vaccines, and targeted protein degraders) for serious unmet medical needs in oncology, nephrology, endocrinology, and rare diseases. Its commercial-stage lead product Efepoetin alfa (GX-E4/Efesa), a long-acting erythropoietin for chronic kidney disease-induced anemia, received its first market approval from Indonesian BPOM in October 2023, with multiple Phase 3 programs (GX-E4, GX-H9) advancing through clinical development globally.
Is Genexine a public or private company?
Genexine is a public company. It is classified as public and is currently operating.
When was Genexine founded?
Genexine was founded in 2015. It employs 51 to 100 people.
Where is Genexine based?
Genexine is headquartered in Seongnam, South Korea, in the Asia region.
Who are Genexine's main competitors?
Direct peers on record are Hanmi Pharmaceutical and Alteogen. Broad incumbents are Celltrion, Samsung Bioepis, Amgen, Roche and Novo Nordisk. Emerging players are Arvinas, NeoImmuneTech and I-Mab Biopharma.
Does Genexine have an API?
No public API is recorded for Genexine.
What industry is Genexine in?
Genexine's product category is Clinical-stage biopharmaceuticals (oncology, nephrology, endocrinology, rare disease). Its primary akta.pro industry code is HLAAAAAK, Therapeutic Enzymes & Enzyme Replacement Therapies (ERT), with a secondary code of HLAAACAM, Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services. Its NAICS code is 325414 and its SIC code is 2836.